治疗高血压的内啡素抗剂:它们的时间终于到来了吗?
1Hypertension and Vascular Research Unit, Lady Davis Institute for Medical Research and Department of Medicine, Sir Mortimer B. Davis-Jewish General Hospital, MGill University, Montreal, Quebec, Canada.
Clinical science (London, England : 1979)
|July 4, 2025
概括
内甲素 (ET) 系统在严重高血压中起作用. 现在批准了一种新的双结尾蛋白受体对抗剂,即阿普罗西坦,用于治疗与其他药物结合时的抗性高血压.
科学领域:
- 心血管医学 心血管医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 在过去的30年里,高血压的新疗法有限.
- 内甲素 (ET) 系统与血压调节和血管重塑有关,特别是在严重高血压模型中.
- 以前的选择性和双重内甲素受体抗剂 (ETAR/ETBR) 没有进入人类高血压的市场.
研究的目的:
- 引入新批准的双内甲素受体对抗剂aprocitentan用于高血压治疗.
- 突出ET抗剂在管理不充分控制的高血压方面的重要性.
主要方法:
- 对双重内末素受体抗剂的临床试验,特别是aprocitentan.
- 评估阿普罗西坦在抗性高血压治疗中的疗效.
主要成果:
- 阿普罗西坦是双重ETAR/ETBR抗剂,已在欧洲和美国获得批准.
- 这种药物在抗性高血压的试验中取得了成功.
- 艾普罗西坦是适用于成人患者,其血压无法通过其他抗高血压药物得到充分控制.
结论:
- 阿普罗西坦的批准标志着高血压药物治疗的重大进展.
- 内甲素受体对抗剂现在是管理难以治疗的高血压的可行的治疗选择.
- 这一发展标志着ET对抗剂在高血压临床管理中的新时代.
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
227
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
227
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
516
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
516
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
893
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
893
Antihypertensive Drugs: Angiotensin II Receptor Blockers
931
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
931
Antihypertensive Drugs: Vasodilators
649
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
649
Antihypertensive Drugs: Direct Renin Inhibitors
835
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
835


